{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=50",
    "query": {
      "intervention": "Injectable saline",
      "page": 50
    },
    "page_size": 10
  },
  "pagination": {
    "page": 50,
    "page_size": 10,
    "total_count": 2101,
    "total_pages": 211,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=51&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=49&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T18:48:19.470Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03486834",
      "title": "V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cytomegalovirus (CMV) Infections"
      ],
      "interventions": [
        {
          "name": "V160",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "16 Years to 35 Years · Female only"
      },
      "enrollment_count": 2200,
      "start_date": "2018-04-30",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Rialto, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486834"
    },
    {
      "nct_id": "NCT00949754",
      "title": "Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "honeybee venom (Apitoxin (Korea) Apitox (USA))",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apimeds, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "35 Years to 85 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-10",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2010-05-05",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 4,
      "location_summary": "Pinellas Park, Florida • Chicago, Illinois • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949754"
    },
    {
      "nct_id": "NCT00937677",
      "title": "Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Tysabri",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 85,
      "start_date": "2007-11",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2011-09-07",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00937677"
    },
    {
      "nct_id": "NCT01658501",
      "title": "Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "50 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "70 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "100 mg PB1023",
          "type": "DRUG"
        },
        {
          "name": "Placebo (0.9% Sodium Chloride)",
          "type": "DRUG"
        },
        {
          "name": "Victoza®",
          "type": "DRUG"
        },
        {
          "name": "Diet and Exercise",
          "type": "OTHER"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        },
        {
          "name": "Metformin and Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 593,
      "start_date": "2012-07",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2015-12-07",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 93,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658501"
    },
    {
      "nct_id": "NCT02498769",
      "title": "Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin Type A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joseph Mathew, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 130,
      "start_date": "2015-09",
      "completion_date": "2018-12-01",
      "has_results": true,
      "last_update_posted_date": "2019-02-22",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02498769"
    },
    {
      "nct_id": "NCT06692907",
      "title": "Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Escherichia Infection"
      ],
      "interventions": [
        {
          "name": "B7A (ETEC challenge strain)",
          "type": "OTHER"
        },
        {
          "name": "CssBA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dmLT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 72,
      "start_date": "2025-03-31",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06692907"
    },
    {
      "nct_id": "NCT03166501",
      "title": "NMDA Receptor Modulation for Hyperarousal in PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depression",
        "Post Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Lanicemine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2018-09-01",
      "completion_date": "2019-11-14",
      "has_results": false,
      "last_update_posted_date": "2020-08-19",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03166501"
    },
    {
      "nct_id": "NCT07282665",
      "title": "A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clostridoides Difficile Associated Disease"
      ],
      "interventions": [
        {
          "name": "C.difficile vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 32500,
      "start_date": "2025-12-10",
      "completion_date": "2029-06-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 142,
      "location_summary": "Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chinle",
          "state": "Arizona"
        },
        {
          "city": "Chinle",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07282665"
    },
    {
      "nct_id": "NCT03352466",
      "title": "NasoShield Study of Safety and Immunogenicity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "NasoShield",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BioThrax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Altimmune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 145,
      "start_date": "2018-01-18",
      "completion_date": "2019-05-13",
      "has_results": false,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 2,
      "location_summary": "Melbourne, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03352466"
    },
    {
      "nct_id": "NCT06989866",
      "title": "RCT to Test Regional Anesthesia Effect on Decreased Opiate Use",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        },
        {
          "name": "Saline (NaCl 0,9 %) (placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United States Naval Medical Center, Portsmouth",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-12-01",
      "completion_date": "2026-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-10-31T18:48:19.470Z",
      "location_count": 1,
      "location_summary": "Portsmouth, Virginia",
      "locations": [
        {
          "city": "Portsmouth",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06989866"
    }
  ]
}